Individual Plaintiff Opioid Cases – An Emerging Litigation

Individual Plaintiff Opioid Cases Now Emerging in The Opiate Litigation

 

 

 

 

 

 

 

 

 

 

Most discussions in the legal community have focused on the “entity” plaintiffs thus far and these entity cases certainly have merit however, our researchers believe the largest number of potential plaintiffs with viable cases against the opioid manufacturers are those claims related to individual plaintiff injuries and deaths.

Learn More About the Opioid Individual Case Emerging Litigation

The  Opioid Individual Case Emerging Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Your PI Firm Has Already Represented Individuals Who May Now Have Viable Opioid Cases

Given the fact that the first opioid prescription a person ever receives often occur due to an auto accident, a work related injury or another injury which results in the filing of a personal injury case, your firm has already represented numerous individuals who now have claims related to opioids. Sign these individual plaintiffs you already have before someone else does

Unlike the entity cases which as a general rule name a host of manufacurers as well as distributors as defendants, some individual opioid cases may be brought against a single manufacturer while others may be filed based on legal theories that will require naming some or all of the alleged “opioid conspirators”.

The “individual case” opioid litigation will be different than a typical mass tort litigation involving a pharmaceutical product. Different claims will exist against different manufacturers and arise from different causes.

The single most important first step for any law firm considering accepting clients with individual opioid cases will be to learn how to properly qualify clients.

Examples of Opioid Claims Arising from FDA Actions

Opana ER: June 2017  U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks.

Codeine and Tramadol Can Cause Breathing Problems for Children

FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women issued on April 20, 2017.

These medicines can cause life-threatening breathing problems in children. Some children and adults break down codeine and tramadol into their active forms faster than other people. That can cause the level of opioids in these people to rise too high and too quickly.

January 2018 FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older

The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for prescription cough and cold medicines containing codeine or hydrocodone to limit the use of these products to adults 18 years and older because the risks of these medicines outweigh their benefits in children younger than 18.

The Individual Opioid cases (arising from a given cause) listed above are only a fraction of the universe of these types of opioid cases.  Attend the May Four Days to Mass Tort Success Course for a broader coverage of the individual case opioid litigation.

Mass Tort Nexus is also hosting a national “Opioid Crisis Summit” July 21-22, 2018 here in Fort Lauderdale

This event will be unlike ANY other opioid conference ever presented to attorneys. CNN, Associated Press, STAT NEWS (The Boston Globe), The Sun-Sentinel, ABC and NBC will be here to cover this event because never before has such a comprehensive group of experts been assembled to explain how the Opioid Crisis began and how it has affected our country. Leading politicians, medical doctors, treatments centers, academics and attorneys will come together to tell the story of what happened from their vast experience in dealing with this crisis, for more than two decades.

WHY DO YOU NEED TO ATTEND THIS EVENT?

Contrary to popular belief, it is not too late to acquire entity cases (state, county, city, union, private insurers, etc.) There are an estimated 10,000 entity cases and less than 1% have been signed. Mass Tort Nexus has the data for every county in the country, along with an index score to arm you with the information to write accurate complaints and customize them in great detail.

The universe of individual cases will potentially be in excess of one million plaintiffs. Over 90 million Americans were prescribed opioids in the last year alone and there is not one segment of society that has not been affected. The only litigation that compares to it in size and scope is the tobacco litigation; however, there is one big difference – the opioid litigation is likely to resolve far more quickly. We will reveal the reasons why. Our keynote speakers include Ohio Lt. Governor Mary Taylor and Dr. Rahul Gupta, Director of Public Health, State of West Virginia and others with real time, day to day experience in dealing with opioid crisis as well as providing solutions.

For complete information on this major Opioid Summit and the nationally prominent guest speakers – follow the link below:

Opioid Crisis Summit by Mass Tort Nexus- July 21-22, 2018 Summit link and Information

 

 

 

 

Read More

NeuroBlate Probe Emerging Litigation

Emerging NeuroBlate Probe Litigation

  

 

 

 

 

 

 

 

 

 

 

 

The NeuroBlate probe made by Moneris Medical, Inc. is a device used during various types of complex neurological surgeries.

March 2018 FDA Communication Excerpt:

ISSUE: The FDA is providing preliminary information about the potential for unintended heating and patient injury with use of the Monteris Medical NeuroBlate probe, which is part of the NeuroBlate System, and bringing to your attention a Class I recall for the device.

A Class I recall is the most serious type of recall and is issued when use of the device may cause serious injuries or death. Monteris issued three product advisories between October and December 2017, which were part of the Class I recall; however, the FDA has concerns that the information provided by Monteris has not sufficiently mitigated the risk of unintended probe tip heating. We are working with the manufacturer to address these concerns.

The device is currently the subject of a voluntary recall which was initiated by the firm, and classified as a Class I Recall by the FDA, due to several instances of unintended heating and damage to the probe, which may have resulted in unintended damage to surrounding brain tissue. The damage to the probe appears to have been caused by an interaction between the thermocouple in the probe, and the MRI environment. These events occurred independent of laser energy delivery, and have been associated with damage to the tip of the probe implanted within the brain (e.g., charring, release of carbon dioxide).

To Learn More About the Emerging NeuroBlate Probe Litigation:

The Emerging Moneris Medical NeuroBlate Probe Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

 For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the Emerging NeuroBlate probe Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements from some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course, see James Onder of The Onder Firm in St. Louis, MO comments below>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Read More

 New Gadolinium Imaging Contrast Agent Emerging Litigation   

Emerging New Gadolinium Imaging Contrast Agent Litigation   

 

Gadolinium Imaging Contrast Agent In The Brain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lawsuits related to Gadolinium Contrast Dyes have previously been consolidated in MDL 1909 on June 6th, 2008. The current issues related to Gadolinium Contrast Dyes are different from those litigated in MDL 1909.

MDL 1909 Defendants: General Electric Company, GE Healthcare, Inc., and GE Healthcare Bio-sciences Corp. (the GE defendants), and Mallinckrodt, Inc.

FDA December 2017 After reviewing available data, the FDA recommended that radiologists consider how much gadolinium might be left behind in a patient’s body when selecting a gadolinium-based contrast agent [GBCA] for an MRI.

The current primary concern related to Gadolinium Contrast Agents relates to the buildup in the brain,  of certain substances contained in these agents.

Gena Norris, wife of actor Chuck Norris recently brought a lawsuit alleging that she fell ill after exposure to gadolinium used in an MRI.

Gadolinium Contrast Agents include:

Ablavar (gadofosveset trisodium)

Dotarem (gadoterate meglumine)

Eovist (gadoxetate disodium)

Gadavist (gadobutrol)

Magnevist (gadopentetate dimeglumine)

MultiHance (gadobenate dimeglumine)

Omniscan (gadodiamide)

OptiMARK (gadoversetamide)

ProHance (gadoteridol)

 To Learn More About the Emerging New Gadolinium Contrast Agent Litigation:    

The emerging New Gadolinium Contrast Agent will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

 

 Course attendees will receive the benefit of a step by step analysis of the emerging New Gadolinium  Contrast using these primary metrics:

 

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 

Read More

 Imodium OTC Emerging Litigation

Emerging Imodium-Over The Counter Litigation

 

IMODIUM PRODUCTS EMERGING LITIGATION

 

 

 

 

 

 

 

 

 

 

 

Imodium (LOPERAMIDE HYDROCHLORIDE) Products include:  Imodium, Imodium A-D, Imodium A-D EZ Chews. Imodium Multi-Symptom Relief . These products are manufactured and or marketed by Janssen Pharmaceuticals  and Johnson and Johnson Consumer Inc. Imodium has been available for over two decades and is one of the most commonly used medications for the treatment of diarrhea symptoms.

The FDA issued a drug safety advisory warning that many people are experiencing serious heart problems after taking high doses of Imodium or taking Imodium in combination with other medications that interact with the drug.

Imodium, Imodium A-D, Imodium A-D EZ Chews and Imodium Multi-Symptom Relief

Many of the drugs that are believed to negatively interact with Imodium are commonly used in combination with Imodium.

A partial list of drugs which are believed to negatively interact with Imodium include:

Tagamet HB (cimetidine) – treat heartburn, GERD symptoms

Zantac (rantidine) – treat heartburn, GERD symptoms

Prevpac – proton-pump inhibitor; used to treat heartburn, acid reflux

Biaxin (clarithromycin) – antibiotic

E.E.S., Ery-Tab, Eryc, Eryped, PCE (erythromycin) – antibiotic

Lopid (gemfibrozil) – treats high cholesterol

Onmel, Sporanox (itraconazole) – anti-fungal medications

Ketoconazole (generic only) – anti-fungal medication

Nuedexta (quinidine) – used to treat mental/mood disorders

Qualaquin (quinine) – anti-malaria drug; also used to treat nocturnal leg cramps

Kaletra, Norvir, Technivie, Viekira Pak (ritonavir) – anti-HIV treatment

To Learn More About the Emerging Imodium OTC Litigation:

The emerging Imodium OTC  Litigation will be used as a case study in the May 18-21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Imodium and Similar Products Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course have endorsed Mass Tort Nexus and the course curriculum, including Annesley DeGaris below>

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Vascular Solutions, Inc. Emerging “Venture Catheters” Recall Litigation

Emerging Venture Catheters Recall Litigation

Vascular Systems, Inc. Venture Catheter Litigation

 

 

 

 

 

 

 

 

 

A Class 1 FDA Recall has been issued by the FDA related to certain Catheters manufactured by Venture Solutions, Inc. between 2015 and 2017.

      FDA Communication Excerpt:

“Vascular Solutions, Inc. is recalling the Venture catheter because there is a risk of the catheter tip splitting or separating during use. Excess material at the tip of the catheter may separate and could enter the patient’s bloodstream. This can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death”

Learn More About the Emerging Venture Catheters  Recall  Litigation

The emerging Venture Catheters Recall will be used as a case study in the May 18-21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging  Venture Catheters Recall  Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Viberzi Emerging Litigation   

 Emerging Viberzi Litigation  

Viberzi Litigation

   

 

 

 

 

 

 

 

 

 

Viberzi made by Allergan received FDA approval subsequent to New Drug Application (NDA:206940) in May of 2015.

Since its approval the makers of Viberzi have flooded the media with advertisements, primarily directed toward women, featuring a now familiar female character wearing a jumpsuit featuring print depicting a portion of the human gastro-intestinal system.

 

FDA Communication Excerpt on Viberzi:

“FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concerns.

Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients. Hospitalizations and deaths due to pancreatitis have been reported with Viberzi use in patients who do not have a gallbladder. Symptoms of pancreatitis have occurred with just one or two doses of Viberzi at the recommended dosage for patients who do not have a gallbladder (75 mg), and who do not consume alcohol.”

Viberzi Emerging Litigation

Gallstone disease is one of the most common of all digestive diseases. The U.S. Centers for Disease Control and Prevention estimates that 6.3 million men and 14.2 million women in the United States have gallbladder disease. There is marked variation in the prevalence between ethnic groups

Approximately 700,000 individuals in the U.S.  have their gallbladder removed each year.

How to Learn More About the Emerging Viberzi Litigation

The emerging Viberzi Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” to register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Viberzi

Litigation, using these primary metrics:

 

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Uloric Emerging Litigation

Emerging Uloric Litigation

 

 

Uloric Litigation

 

 

 

 

 

 

 

 

 

 

Uloric made by Takeda Pharmaceuticals gained FDA approval subsequent to New Drug Application (NDA: 021856) in February 2009.

Takeda Pharmaceuticals is facing multiple Qui Tam lawsuits filed by a former safety consultant for the company.  These suits that the company withheld information about dangerous side effects related to Uloric, including kidney problems, liver damage, bone marrow failure, drug interactions and more.

Gout, a type of arthritis that occurs when uric acid crystals build up in the joints. Gout has been found to be more common in men than in women Gout is believed affects about 8.3 million people, or 4% of the U.S. population.

Uloric was the first new drug approved to treat Gout in 40 years. Unfortunately, this new treatment which promised relief for those who suffer from Gout, appears to have numerous significant and potentially life threatening side effects that Takeda never warned the public about.

Learn More About the Emerging Uloric Litigation

The emerging Uloric Litigation will be used as a case study in the May 18-21, 2018 Mass Tort Nexus “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Uloric

Litigation, using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including CNN Legal Analyst Mark O’Mara>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Read More

Varubi Emerging Litigation

 Emerging  Varubi Litigation

 

 

 

 

 

 

 

 

 

 

 

VARUBI®(rolapitant) was originally developed by Schering-Plough Corp. and after the merger with Merck & Company they began marketing in November 2009. Tesaro Inc. has since licensed Varubi.

January 2018 FDA Communication Excerpt: 

“Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of Varubi (rolapitant) injectable emulsion. Most reactions have occurred within the first few minutes of administration. Symptoms of anaphylaxis can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping, abdominal pain or vomiting; back pain or chest pain; hypotension or shock. Anaphylaxis or anaphylactic shock are serious medical conditions which if not promptly treated can result in death”

Where to Learn More About the Emerging Varubi Litigation

The emerging Varubi Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Varubi Litigation using these primary metrics:

 


Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course>

 

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Read More

Keytruda Emerging Litigation

Emerging Keytruda Litigation

Keytruda Litigation

 

 

 

 

 

 

 

 

 

 

 

 

 

Keytruda (pembrolizumab) made by Merck Sharpe Dohme first received FDA approval pursuant to Biologic License Application (BLA: 125514) in September of 2014.

Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Keytruda when combined with other medications indicated for the treatment of multiple myeloma may cause death in some patients according to federal drug regulators.

Two post approval clinic trials, Keynote-185 and Keynote-185 resulted in a significant number of deaths among patients participating in the studies.

Learn More About the Emerging Keytruda Litigation

The emerging Keytruda Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

 

Course attendees will receive the benefit of a step by step analysis of the emerging Keytruda Litigation, using these primary metrics:

 

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course>

 

 

 

 

 

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 

Read More

Emerging Tasigna Litigation

 Tasigna Emerging Litigation

Tasigna by Novartis AG

Tasigna (NILOTINIB HYDROCHLORIDE MONOHYDRATE) made by Novartis gained FDA approval in October 2007, New Drug Application (NDA: 022068)

Tasigna is FDA approved for the treatment of accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia  in adult patients resistant to or intolerant to prior therapy.

Unwarned adverse events potentially associated with Tasigna include accelerated atherosclerosis. This life-threatening condition occurs when plaque accumulates in the arteries. As plague builds up in the arteries, a reduction in blood flow can occur, resulting in a large number of secondary conditions which in some cases can lead to death.

How to Learn More About the Emerging Tasigna Litigation

The emerging Tasgina Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” to register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the emerging Tasigna Litigation, using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

 

]

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Read More